Lanping Ma

Title: The Innovative Contributions of Lanping Ma

Introduction

Lanping Ma is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of biotechnology, particularly in the development of targeted therapies for cancer treatment. With a total of 7 patents to his name, Ma's work is characterized by its focus on high specificity and efficacy in targeting tumor cells.

Latest Patents

Among his latest patents is a tissue factor-targeted antibody-drug conjugate (ADC). This innovative ADC is designed to bind to the tissue factor (TF) antigen with high specificity. It boasts high affinity, low immunogenicity, and significant anti-tumor activity, making it a promising candidate for cancer therapies. Another notable patent involves an AXL-targeting antibody and antibody-drug conjugate. This invention includes a method for preparing the antibody and ADC, which can effectively bind to purified human AXL protein and multiple AXL proteins on tumor cell surfaces. The AXL antibody-drug conjugate demonstrates remarkable performance against tumors with high AXL expression.

Career Highlights

Lanping Ma has held positions at prestigious institutions such as the Chinese Academy of Sciences and Fudan University. His work at these organizations has allowed him to collaborate with leading researchers and contribute to groundbreaking advancements in medical science.

Collaborations

Some of his notable coworkers include Jingkang Shen and Tao Meng. Their collaborative efforts have further enhanced the impact of Ma's inventions in the field of biotechnology.

Conclusion

Lanping Ma's innovative work in developing targeted therapies showcases his commitment to advancing cancer treatment. His contributions through patents and collaborations highlight the importance of research in improving patient outcomes.